He is BSing as usual. That theory is just non sense along with 10 year survival data. Why would survaxm share patient level data with a competitor? Also, if NICE is not convinced with 9 year survival data then it wont be convinced with 10 year either.
All this while LP has been diluting in low .20s and is ok with wasting time like that, LOL!
Although, what it tells you is that don’t expect approval this quarter. All time lows coming!
In fact, I’d go on to bet that approval is highly unlikely this year. New theories and excuses will pop come end of the quarter. The reality is that NWBO has been unable to respond to MHRA concerns for many months. MHRA has said for many months that the ball is in NWBO’s court and that we should follow up with them.
Market Data 
Markets 
AI
